The next-generation triple-receptor peptide behind the largest weight reductions reported in obesity trials to date. Pre-loaded, third-party tested, cold-chain delivered across Europe.
Retatrutide is a single peptide that activates three metabolic receptors at once — GLP-1, GIP and glucagon. Most weight-management peptides hit one or two of these. Hitting all three is why it has drawn more attention than any compound in the category.
In practice those three levers do different jobs: GLP-1 slows gastric emptying and reduces appetite, GIP supports insulin sensitivity and appears to improve tolerability, and glucagon-receptor activation increases energy expenditure. The result is appetite suppression paired with a higher metabolic burn rate, rather than appetite suppression alone.
Retatrutide is an investigational compound. The figures below come from published, peer-reviewed clinical trials of the compound — they are not claims about Body Pharm's product, and individual results vary.
A separate Phase 2 trial in adults with type 2 diabetes reported a mean weight reduction of roughly 16.9% at 36 weeks (Rosenstock J, et al. Lancet. 2023;402(10401):529–544).
Trial participants received the investigational formulation under clinical supervision, alongside diet and exercise counselling. Retatrutide is not approved by the EMA or FDA. These results describe the compound in research settings and are not a promise of outcome.
Both pens contain the same compound at the same concentration standard — the 64 mg pen simply holds double the peptide, which lowers your cost per milligram and lasts through a longer titration.
Best if you're starting out
Most protocols begin at a low weekly dose and titrate up every four weeks. The 32 mg pen covers the early phase without over-committing.
För närvarande inte tillgänglig i ditt land — ställ dig på väntelistan så mejlar vi dig när den finns tillgänglig.
Best value per mg
Once you've titrated past the starting doses, the 64 mg pen carries you further per pen and brings the price per milligram down significantly.
För närvarande inte tillgänglig i ditt land — ställ dig på väntelistan så mejlar vi dig när den finns tillgänglig.
No vials, no bacteriostatic water, no dosing math. Dial your dose, press, done — the same format used for modern diabetes care.
Independent labs verify identity, purity and sterility before anything ships. Scan the QR on your pen for the certificate of analysis for your exact lot.
Insulated packaging holds 2–8°C from our facility to your door. Orders placed before 12:00 ship the same day; delivery takes 3–5 business days.
5 pens takes 10% off, 10 pens takes 15% off — applied automatically at checkout and combinable across compounds.
"Sex veckor på Retatrutide och mina blodprover är de bästa på ett decennium. Min husläkare frågade vad som hade förändrats."
"Den förfyllda pennan förändrade allt. Inga ampuller, ingen beredningsmatematik — jag vrider fram min dos före läggdags. Sömnen var märkbart annorlunda vid vecka tre."
"Jag skannade QR-koden på min penna och fick det faktiska labbcertifikatet för min batch. Den nivån av transparens är skälet till att jag flyttade över hela mitt protokoll."
Semaglutide is a single agonist (GLP-1). Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide adds a third receptor — glucagon — which is associated with increased energy expenditure on top of appetite reduction. That third lever is the reason the Phase 2 weight-reduction figures came in higher than those reported for the earlier compounds.
The 32 mg pen holds 32 mg in 3 mL; the 64 mg pen holds 64 mg in 3 mL. How long a pen lasts depends entirely on your prescribed weekly dose — trial protocols ran from 1 mg up to 12 mg weekly with titration every four weeks, so a pen's duration changes as you titrate.
No. Retatrutide is an investigational compound still in clinical development and is not approved by the EMA or FDA. It should only be used under the supervision of a qualified clinician, who should set your dose and monitor your bloodwork.
The Phase 2 trial reported that the most common adverse events were gastrointestinal — nausea, diarrhoea, vomiting and constipation — and were generally mild to moderate and dose-related. Slow titration is the standard approach to reducing them. Discuss your full medical history with your clinician before starting.
Pens are temperature-sensitive and ship in insulated cold-chain packaging held between 2–8°C. Refrigerate on arrival. If a pen arrives broken or isn't working, we replace it free of charge once you share photos or a short video showing the fault.
Yes. Ordering and joining a waitlist both require an account, which is also where your batch certificates and order history live.
Both strengths ship cold-chain with a batch certificate of analysis. Bulk pricing applies automatically.
Choose your penEducational content only — not medical advice. Retatrutide is an investigational compound not approved by the EMA. Peptide protocols should be run under the supervision of a qualified clinician. These statements have not been evaluated by the EMA.